[Pancreatoxicity during neoadjuvant and adjuvant chemotherapy of HER-negative breast cancer].
Kaziulin
A N
AN
Biakhov
M Iu
MIu
Koroleva
I A
IA
Kozlov
S V
SV
Kucheriavyĭ
Iu A
IuA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000681:Amylases / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008049:Lipase / Q000097:blood; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010179:Pancreas / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000201:enzymology; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology; D020893:Receptor, ErbB-3 / Q000096:biosynthesis*; D012189:Retrospective Studies; D014463:Ultrasonography
D004317:Doxorubicin; D020893:Receptor, ErbB-3; D008049:Lipase; D000681:Amylases; D017239:Paclitaxel